Evaluation Period vs Control Period: Antiretroviral Therapy (ART) Receipt
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.927 | 0.918 | 0.934 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.964 | 0.958 | 0.969 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0375 | -0.0477 | -0.0276 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.961 | 0.951 | 0.971 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.47 | 0.384 | 0.576 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Evaluation Period than on Control Period | 26.7 | 21 | 36.3 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Evaluation Period | Patients monitored during the evaluation period. | 3,508 | 3,786 | OG001 | ClinicalTrials.gov |
| Group 2 | Control Period | Patients monitored during the control period. | 4,106 | 4,259 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Antiretroviral Therapy (ART) Receipt | ClinicalTrials.gov |
| Description | ART receipt will be defined as at least 180 days of three concurrent antiretroviral agents in the 6-month interval based on prescriptions in the electronic medical record. | ClinicalTrials.gov |
| Time frame | 12 months | ClinicalTrials.gov |
| Population | All patients monitored across all (multiple) control and evaluation periods. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation | ClinicalTrials.gov |
| NCT number | NCT02907944 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Substance-related Disorders | ClinicalTrials.gov |
| Interventions | Implementation Facilitation | ClinicalTrials.gov |
| Lead sponsor | Yale University | ClinicalTrials.gov |
| Results first posted | 2023-05-08 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02907944?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.